ArticleIndian journal of ophthalmology2026
Report 2: Macular edema after acute retinal necrosis-A difficult crossroad in management.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate cases of acute retinal necrosis (ARN) with macular edema (ME) and review the literature on management strategies for ME in ARN.
methodsA retrospective analysis was conducted on ME cases secondary to ARN from a cohort of 119 patients with ARN, treated at a tertiary eye care center between 2010 and 2022. Patients with a minimum follow-up of 6 months were included, while those with underlying immunosuppressive disease (e.g. HIV infection) or receiving immunosuppressive therapy or with incomplete documentation were excluded.
resultsME developed in 9.7% of ARN patients among the cohort of 119 patients. The mean age was 41.3 ± 12.3 years (range: 10-60 years), and ten (83.3%) were male. All patients received systemic antiviral therapy and oral corticosteroids. Of 12 affected eyes, eight underwent pars plana vitrectomy with silicone oil tamponade for retinal detachment, and one underwent cataract surgery before ME onset. Following ME development, nine eyes received topical steroids and eight were started on topical NSAIDs, while oral corticosteroids were initiated in all cases. Antiviral prophylaxis was reinitiated in five eyes. Periocular triamcinolone injection was given in one eye, and intravitreal dexamethasone implant was administered thrice in another patient. The median central foveal thickness at diagnosis was 437 µm (range: 342-1284 µm), reducing to 374.5 µm (range: 254-1056 µm) after treatment.
conclusionME is a rare but visually disabling complication of ARN. Its management remains challenging, and the role of local steroid therapy warrants further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.